Consensus WuXi Biologics (Cayman) Inc. OTC Markets

Equities

WXXWY

US98260N1081

Market Closed - OTC Markets Other stock markets 20:25:05 07/06/2024 BST			5-day change	1st Jan Change
2.813 ^USD	-3.48%		-0.95%	-62.24%

06-01	US lawmakers ask FBI for briefing on GenScript Biotech's links to China	RE
05-31	US lawmakers ask FBI for briefing on GenScript Biotech's links to China	RE

Evolution of the average Target Price on WuXi Biologics (Cayman) Inc.

Price target over the last 5 years

History of analyst recommendation changes

c61e4a7c033de54db1f9996267b.-qEItvykZJGi7sVRksRQqVrLV7V-cwPhz2UFYNMrkX4.wsd8-MXtF_T7io1n6ukgxAyPOfoQHGrZhRVQL4RE3DfJ9FfFm5AhovuXrg~bdcbfb7fda3e894409c6cb551927f587

Analyst Recommendations on WuXi Biologics (Cayman) Inc.

Wuxi Biologics (Cayman) Maintains it is Not a Security Threat After House Bill Changes; Stocks Drop 3%	05-17	MT
Nomura Adjusts Wuxi Biologics' Price Target to HK$53.65 From HK$58.44, Keeps at Buy	03-01	MT
Hong Kong Stocks Rebound Over Unchanged Fed Rates; Wuxi Up 3%	02-01	MT
Nomura Adjusts Wuxi Biologics’ Price Target to HK$58.44 From HK$82.69, Keeps at Buy	12-05	MT
Nomura Adjusts Wuxi Biologics' Price Target to HK$82.69 From HK$86.68, Keeps at Buy	24/07/23	MT
Nomura Adjusts WuXi Biologics (Cayman)'s Price Target to HK$86.86 From HK$94.91, Keeps at Buy	21/06/23	MT
Nomura Adjusts WuXi Biologics' Price Target to HK$94.91 From HK$97.78, Keeps at Buy	14/02/23	MT
New energy shares drag China stocks lower, Fed rate-decision jitters weigh	15/09/22	RE
UBS Adjusts Wuxi Biologics’ Price Target to HK$113.12 From HK$110.67, Keeps at Buy	22/08/22	MT
Nomura Adjusts WuXi Biologics' Price Target to HK$97.78 From HK$95.75, Keeps at Buy	05/08/22	MT
UBS Adjusts Wuxi Biologics (Cayman)'s Price Target to HK$95.75 From HK$100.87, Keeps at Buy	09/06/22	MT
China stocks rise on higher-than-expected borrowing rate cut; foreign inflows surge	20/05/22	RE
UBS Adjusts Wuxi Biologics' Price Target to HK$110.67 From HK$142, Keeps at Buy	29/03/22	MT
Nomura Adjusts WuXi Biologics' Price Target to HK$100.87 From HK$103.28, Keeps at Buy	24/03/22	MT
Nomura Adjusts WuXi Biologics' Price Target to HK$103.28 From HK$149.92, Keeps at Buy	17/03/22	MT
China stocks fall as virus worries, Fed rate hike bets weigh; Hong Kong up	11/01/22	RE
WUXI BIOLOGICS CAYMAN : Nomura Adjusts WuXi Biologics' Price Target to HK$116.8 From HK$213.1, Keeps at Buy	29/03/21	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

10.56 CNY

Average target price

24.52 CNY

Spread / Average Target

+132.32%

High Price Target

67.84 CNY

Spread / Highest target

+542.66%

Low Price Target

11.08 CNY

Spread / Lowest Target

+5.01%

Consensus detail

Consensus revision (last 18 months)

Analysts covering WuXi Biologics (Cayman) Inc.

Nomura
UBS

Ratings for WuXi Biologics (Cayman) Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar